key: cord-0938538-kjb94z5u authors: Zervou, Fainareti N.; Louie, Ping; Stachel, Anna; Zacharioudakis, Ioannis M.; Ortiz‐Mendez, Yadira; Thomas, Kristen; Aguero‐Rosenfeld, Maria E. title: SARS‐CoV‐2 antibodies: IgA correlates with severity of disease in early COVID‐19 infection date: 2021-05-12 journal: J Med Virol DOI: 10.1002/jmv.27058 sha: 2f29a3c4ffb28edf6a63f6f6a2622abbf38d0b65 doc_id: 938538 cord_uid: kjb94z5u Timing of detection of immunoglobulin G (IgG), immunoglobulin A (IgA), and immunoglobulin M (IgM) antibodies against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), and their use to support the diagnosis are of increasing interest. We used the Gold Standard Diagnostics ELISA to evaluate the kinetics of SARS‐CoV‐2 IgG, IgA, and IgM antibodies in sera of 82 hospitalized patients with polymerase chain reaction (PCR)‐confirmed coronavirus disease 2019 (COVID‐19). Serum samples were collected 1–59 days post‐onset of symptoms (PoS) and we examined the association of age, sex, disease severity, and symptoms' duration with antibody levels. We also tested sera of 100 ambulatory hospital employees with PCR‐confirmed COVID‐19 and samples collected during convalescence, 35–57 days PoS. All but four of the admitted patients (95.1%) developed antibodies to SARS‐CoV‐2. Antibodies were detected within 7 days PoS; IgA in 60.0%, IgM in 53.3%, and IgG in 46.7% of samples. IgG positivity increased to 100% on Day 21. We did not observe significant differences in the rate of antibody development in regard to age and sex. IgA levels were highest in patients with a severe and critical illness. In multiple regression analyses, only IgA levels were statistically significantly correlated with critical disease (p = .05) regardless of age, sex, and duration of symptoms. Among 100 ambulatory hospital employees who had antibody testing after 4 weeks PoS only 10% had positive IgA antibodies. The most frequently isolated isotype in sera of employees after 30 days PoS was IgG (88%). IgA was the predominant immunoglobulin in early disease and correlated independently with a critical illness. IgG antibodies remained detectable in almost 90% of samples collected up to two months after infection. Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus by nucleic acid amplification of viral RNA is the gold standard for the diagnosis of this newly emerging pathogen that causes coronavirus disease-19 , that has led to the largest pandemic of this century. The detection of antibodies can be helpful in confirming the infection, [1] [2] [3] understanding the timing of the infection, 4 and determining the presence of neutralizing antibodies that may aid in the elimination of the virus and perhaps protection against re-infection. 5, 6 Serology methods employed for COVID-19 have utilized several immunogenic antigens of SARS-CoV-2 that include the S (Spike) protein, its subunits S1 and S2, and its receptor-binding domain (RBD) as well as the Nucleocapsid protein (N). 7 Although assays using the S antigen have shown less cross-reactivity with human coronaviruses, including the related Sarbecovirus group, SARS-CoV, and MERS-CoV, the N antigen is more immunoreactive. 8 Evaluation of these assays, mostly from studies abroad, have determined that antibodies to SARS-CoV-2 appear early in the disease course. 9 Studies investigating the kinetics of the antibody response have reported the early appearance of immunoglobulin A (IgA) antibodies regardless of the antigens used in the immunoassay. 10 In the present study, we used the Gold Standard Diagnostic To investigate the specificity of the ELISA assays we included 54 serum samples that were collected before the COVID-19 pandemic All calculations were performed using the Stata v15.0 software package (Stata Corporation). Categorical variables were presented as percentages and were compared by the χ 2 or Fischer exact test using an alpha of 0.05. Continuous variables were presented as means with SD and range and were compared by Student's t-test. Univariate analysis was performed to study the association of the development and levels of different antibody isotypes with age and sex. Also, a multiple regression analysis was performed to examine the association of the age, sex, duration of symptoms, and disease severity with the IgG, IgM, and IgA antibody levels as determined by ELISA units. The Strengthening the Reporting of Observational Studies in Epidemiology guidelines were followed in the preparation of this manuscript. The study population consisted of 82 hospitalized patients who were (Table 1) . Eleven (13.6%) patients had mild disease, 15 (18.5%) had moderate and 55 (67.9%) had the severe or critical disease. All 100 hospital employees who were diagnosed with COVID-19 were managed on an outpatient basis. The rate of antibody isotype development did not show significant differences between patients greater and less than 65 years of age and IgG (p < .01) levels correlated significantly with disease severity. In multiple regression analyses, only IgA levels were found to be associated with critical disease (p = .05) after adjustment for age, sex, and duration of symptoms (Table 3) Prior studies conducted in Europe and China support our findings. Cervia et al. using commercial ELISA using S1 protein as antigen showed that IgA antibodies in serum appeared within 3-4 days postonset of symptoms among patients with severe disease. 12 20 These authors, however, found that the Euroimmun IgA assay had lower specificity than the IgG assay. Ten samples from patients not diagnosed with COVID-19 had IgA reactivity. Similarly, Okba et al. 21 found that commercial assays using S1 as antigen exhibited lower specificity of IgA antibodies as compared with IgG assays. The source of antigen used for antibody assay detection is of importance when analyzing performance and cross-reactivities. A notable finding in the present study is our observation that IgA antibody levels correlated with disease severity and this remained significant after adjusting for age, gender, and duration of symptoms. The fact that IgA levels correlated with disease severity might be attributed to higher immune responsiveness of the respiratory sys- Serology testing in the COVID-19 pandemic response Laboratory diagnosis of COVID-19: current issues and challenges Early detection of SARS-CoV-2 antibodies in COVID-19 patients as a serologic marker of infection Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild COVID-19 Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients The nucleocapsid protein of SARS-CoV-2: a target for vaccine development Infectious Diseases Society of America Guidelines on the diagnosis of COVID-19: serologic testing Serum IgA, IgM, and IgG responses in COVID-19 Clinical management of COVID-19. Interim guidance Systemic and mucosal antibody secretion specific to SARS-CoV-2 during mild versus severe COVID-19. bioRxiv Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients Profiling early humoral response to diagnose novel coronavirus disease (COVID-19) Profiles of antibody responses against severe acute respiratory syndrome coronavirus recombinant proteins and their potential use as diagnostic markers Early detection of antibodies against various structural proteins of the SARS-associated coronavirus in SARS patients Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings Humoral immune response to SARS-CoV-2 Performance characteristics of four high-throughput immunoassays for detection of IgG antibodies against SARS-CoV-2 Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA assay for detection of IgA and IgG antibodies Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients SARS-CoV-2 antibodies: IgA correlates with severity of disease in early COVID-19 infection The authors declare that there are no conflict of interests. The data that support the findings of this study are available from the corresponding author upon reasonable request. http://orcid.org/0000-0002-6192-7403